United States Of America to India: Dexamethasone Import Trade Route

The United States Of America to India Dexamethasone corridor is one of India's established pharmaceutical import routes from United States Of America, with 3 shipments documented worth a combined $10.5K USD. The route is dominated by ESPEE BIOPHARMA AND FINECHEM LLC, which alone accounts for roughly 64% of all import value, reflecting the consolidated nature of United States Of America's dexamethasone export sector.

Across 2 active United States Of America suppliers, the average shipment value stands at $3.5K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Freight is split between sea (65%) and air (15%), suggesting a mix of scheduled bulk orders and time-sensitive consignments.

Shipment activity peaks during April–June, with an average transit time of 28 days port-to-port. The route has recorded an annual growth rate of 24.6%, placing it at rank #7 among India's top dexamethasone import origins globally.

On the Indian buyer side, key Indian importers include ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMITED, DR REDDY S LABORATORIES LIMITED. ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMITED is the single largest Indian importer with 1 shipments valued at $6.7K USD.

India's dexamethasone imports from United States Of America are driven primarily by a handful of large-scale United States Of America manufacturers. ESPEE BIOPHARMA AND FINECHEM LLC with 1 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 2 active exporters signals a competitive but concentrated market — Indian buyers benefit from United States Of America supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — ESPEE BIOPHARMA AND FINECHEM LLC, AMSTERDAM PHARMA(APTEKA RX INC ) — together account for 100% of total trade value on this route. The average shipment value of $3.5K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

Beyond the primary product category, shipments on this route include closely related formulations such as ciprofloxacin 0.3% and dexamethasone 0.1% 0.3%/0.1%(ciprodex)(pack size:1x7.5 ml) and ciprofloxacin 0.3% and dexamethasone 0.1% 0.3/0.1% (ciprodex)(pack size:1 x 7.5 ml), suggesting that Indian buyers tend to consolidate orders across related product lines from the same United States Of America supplier.

On the buying side, ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMITED is the largest importer with 1 shipments worth $6.7K USD — representing 64% of all dexamethasone imports from United States Of America on this route.